Evidence map›Paper›PMID 38285766›Full record

SynthesisAsian Pacific journal of cancer prevention : APJCP2024

Association between XRCC2 Arg188His Polymorphism and Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.

Seyed Alireza Dastgheib, Soheila Sayad, Sepideh Azizi, Nazanin Hajizadeh, Fatemeh Asadian, Mojgan Karimi-Zarchi, Maedeh Barahman, Amirmaoud Shiri, Mohammad Manzourolhojeh, Kazem Aghili and 1 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Seyed Alireza DastgheibDepartment of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Soheila SayadDepartment of Surgery, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
Sepideh AziziAkbarabadi Cilinical Research Development Unit, Iran University of Medical Sciences, Tehran, Iran.
Nazanin HajizadehPreventative Gynecology Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemeh AsadianDepartment of Medical Laboratory Sciences, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran.
Mojgan Karimi-ZarchiDepartment of Obstetrics and Gynecology, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran.
Maedeh BarahmanDepartment of Radiation Oncology, Firoozgar Hospital, Firoozgar Clinical Research Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran.
Amirmaoud ShiriStudent Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad ManzourolhojehMother and Newborn Health Research Center, Shahid Sadoughi Hospital, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Kazem AghiliDepartment of Radiology, Shahid Rahnemoon Hospital , School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Hossein NeamatzadehMother and Newborn Health Research Center, Shahid Sadoughi Hospital, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Iran University of Medical Sciences · IRShahid Sadoughi University of Medical Sciences and Health Services · IRShiraz University of Medical Sciences · IRFiroozgar General Hospital · IRImam Hossein Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is one of the most common cancers in the world and leading cause of cancer-related death among women. Several studies indicated that Arg188His (rs3218536) polymorphism of X-ray repair cross-complementing 2 (XRCC2) may be associated with breast cancer risk. However, this association remains ambiguous. Thus, we performed a meta-analysis to provide more precise conclusion on this issue. A comprehensive search in PubMed, Google Scholar and ISI Web of Science was performed to select all relevant studies. Odds ratios (OR) with corresponding 95% confidence intervals (CI) were applied to assess the strength of the relationships. A total of 17 studies with 5694 breast cancer cases and 6450 healthy subjects were identified. The pooled data revealed that XRCC2 Arg188His polymorphism was marginally with susceptibility to breast cancer globally under the heterozygote contrast (OR = 0.929, 95% CI = 0.873-0.987, p=0.018). Moreover, subgroup analysis by ethnicity revealed that this polymorphism was associated with breast cancer risk among Caucasians. On the whole, the present study demonstrates that the XRCC2 Arg188His polymorphism may contribute to an increased risk of breast cancer.

Indexed as

Breast NeoplasmsDNA-Binding ProteinsCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotideX-RaysDNA-Binding ProteinsXRCC2 protein, humanArg188Hisbreast cancerMeta-analysisPolymorphismXRCC2

Identifiers

PMID38285766
PMCPMC10911734
OpenAlexW4391305047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.